AzTrials
AzTrials

Surgical Site ReactionPIMSNCT01341444

The Use of the Prevena Incision Management System (PIMS) on Closed Incisions in Renal Transplant Subjects

A study testing Prevena Incision Management System in people with Surgical Site Reaction, run by KCI USA, Inc at 1 site in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

This study is being conducted to see how safe and effective the Prevena Incision Management System "Prevena" is when placed over a renal transplantation incision. Prevena provides negative pressure (suction) wound therapy. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Surgical Site Reaction
What is being tested?
Prevena Incision Management System
Type of treatment
Medical device
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
63 participants
Where
1 siteUnited States
Study dates
Aug 2013to May 2016
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Pre-operative Inclusion Criteria

The Subject:

  1. is an adult ≥ 18 years old of either gender
  2. is able to provide their own informed consent Protocol: AHS.2012.Prevena.Cooper.01 v 4.0 Confidential/Property of KCI USA, Inc. Page 6 of 71
  3. will undergo open renal transplant surgery within the next 30 days
  4. will require a surgical incision able to be covered completely by the PIMS dressing
  5. is pre-operatively assessed to undergo a procedure with a CDC Wound Classification of:
  6. Class I (Clean): An uninfected operative wound in which no inflammation is encountered and the respiratory, alimentary, genital, or uninfected urinary tract is not entered
  • OR -
  1. Class II (Clean Contaminated): An operative wound in which the respiratory, alimentary, genital, or uninfected urinary tract are entered under controlled conditions and without unusual contamination
  2. is willing and able to return for all scheduled and required study visits
  3. if female, must test negative on serum pregnancy test
  4. if a female of child-bearing potential, must be willing to utilize an acceptable method of birth control (e.g., birth control pills, condom with spermicide, diaphragm with spermicide, implants, IUD, injections, vaginal rings, hormonal skin patch, etc.) for the duration of study participation
  5. is not concurrently enrolled in a clinical trial which may impact subject health or the surgical incision site

Intra-operative Inclusion Criteria Subjects must meet the following intra-operative inclusion criteria to be eligible for randomization.

The Subject:

  1. continues to meet all pre-operative inclusion criteria
  2. has undergone a Class I or II CDC Wound Classification procedure resulting in a closed surgical incision able to be covered completely by the PIMS dressing

Pre-operative Exclusion Criteria

The Subject:

  1. has a BMI < 18.5 kg/m2 and > 40 kg/m2
  2. has a systemic infection at the time of open renal transplant surgery
  3. has a remote-site skin infection at the time of open renal transplant surgery
  4. is preoperatively assessed to undergo a procedure with a CDC Wound Classification of:
  5. Class III (Contaminated): Open, fresh, accidental wounds, and/or major breaks in sterile technique or gross spillage from the gastrointestinal tract
  • OR -
  1. Class IV (Dirty-Infected): Old traumatic wounds with retained devitalized tissue and those that involve existing clinical infection or perforated viscera
  2. has a known allergy or hypersensitivity to silver, or drape materials that contain acrylic adhesives

Intra-Operative Exclusion Criteria Subjects who meet any of the following intra-operative exclusion criteria are considered screen failures and are not eligible for randomization.

The Subject:

  1. is found to meet any of the pre-operative exclusion criteria
  2. has obvious contamination of the surgical incision
  3. requires external surgical drains that will be covered by the PIMS dressing
  4. is determined to have a CDC Wound Classification of:
  5. Class III (Contaminated): Open, fresh, accidental wounds, and/or major breaks in sterile technique or gross spillage from the gastrointestinal tract
  • OR -
  1. Class IV (Dirty-Infected): Old traumatic wounds with retained devitalized tissue and those that involve existing clinical infection or perforated viscera Protocol: AHS.2012.Prevena.Cooper.01 v 4.0 Confidential/Property of KCI USA, Inc. Page 8 of 71
  2. requires a transfusion, has disseminated-intravascular coagulopathy (DIC) or other medical or surgical conditions during open renal transplant surgery deemed by the Investigator to pose a prohibitively high risk for surgical re-exploration
  3. is deemed unable to continue in the study by the Investigator as the Subject's safety or well-being may be jeopardized.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia, 20007

Other trials in United States

About this study

Official title: The Use of the Prevena Incision Management System on Closed Recipient Site Incisions in Renal Transplant Subjects

This study is being conducted to see how safe and effective the Prevena Incision Management System "Prevena" is when placed over a renal transplantation incision. Prevena provides negative pressure (suction) wound therapy. Prevena will be tested while applied during the time each subject is hospitalized and up to 5 days after the surgery. Prevena is a small portable negative pressure device which consists of a therapy unit that delivers negative pressure. It also includes a dressing system that is intended for use over closed incisions after surgery.

The intent of this study is to evaluate Prevena versus the standard care that a doctor would use normally after a kidney transplant.

Read the detailed description

This is a randomized, single-center, comparative interventional study looking at the effect of Prevena™ on renal transplant surgical Subjects compared to a control arm treated with the standard-of-care wound dressing. The prospective, post-marketing clinical study described in this protocol will assess the effectiveness and functional performance of PrevenaTM in this clinical indication.

Being tested
Prevena Incision Management System, Standard of Care for Surgical Incisions

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Prevena Incision Management SystemDevice

    It is intended to manage the environment of surgical incisions that continue to drain following sutured or stapled closure by maintaining a closed environment and removing exudate via the application of negative pressure wound therapy (NPWT).

  • Standard of Care for Surgical IncisionsOther

    Sterile 4X4 Non-Penetrable barrier

Study groups in NCT01341444
Study groupRoleWhat they receive
Prevena Incision Management SystemExperimentalNegative Pressure Therapy Device
Receives: Device: Prevena Incision Management System
Standard of Care for Surgical IncisionsPlacebo comparatorSterile gauze and a non-penetrable barrier
Receives: Other: Standard of Care for Surgical Incisions

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants With Surgical Site Complications (SSCs)

    The primary objective to compare short-term surgical incision-related clinical outcomes in Subjects undergoing open renal transplant surgery when treated with Prevena vs. the standard-of-care wound dressing. Clinical outcomes of interest are defined as Surgical Site Complications (SSCs) that include incisional fluid accumulation (i.e. seroma, hematoma, abscess), dehiscence, surgical site infection (SSI). These outcomes will be compared to a control group consisting of subjects screened for the same inclusion/exclusion criteria but treated with standard-of-care incision dressing.

    Measured: 62 Days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Apr 2011 (estimated)
  2. Study startAug 2013
  3. Primary completionMay 2016
  4. Study completionMay 2016

Why it stopped: Enrollment Difficulties

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
63 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01341444
Sponsor's protocol ID
AHS.2012.Prevena.Cooper.01
Acronym
PIMS
Status last verified
Oct 2024
First submitted
19 Apr 2011
Last updated
16 Oct 2024
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A study testing Prevena Incision Management System in people with Surgical Site Reaction, run by KCI USA, Inc at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 16 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 2 Jul 2017). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants With Surgical Site Complications (SSCs) (time frame: 62 Days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Oct 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in